{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:45:02Z","timestamp":1789753502497,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jaad.2016.07.034","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T03:22:02Z","timestamp":1475205722000},"page":"1156-1161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials"],"prefix":"10.1016","volume":"75","author":[{"given":"Alexandra B.","family":"Kimball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkeleida","family":"Nika\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Edson-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orin","family":"Goldblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.07.034_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1477-7525-1-53","article-title":"Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials","volume":"1","author":"Shikiar","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2016.07.034_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.034_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2133.1995.tb05019.x","article-title":"The effect of severe of psoriasis on the quality of life of 369 patients","volume":"132","author":"Finlay","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.034_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2340\/00015555-0851","article-title":"Pruritus is an important factor negatively influencing the well-being of psoriatic patients","volume":"90","author":"Reich","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.07.034_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2340\/00015555-1126","article-title":"Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire","volume":"91","author":"O'Neill","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.07.034_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1468-3083.2008.02591.x","article-title":"Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study","volume":"22","author":"Amatya","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.07.034_bib7","series-title":"Committee for medicinal products for human use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis","year":"2004"},{"key":"10.1016\/j.jaad.2016.07.034_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.034_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2013.09.030","article-title":"Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity","volume":"70","author":"Roblin","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.034_bib10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/bjd.13065","article-title":"Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial","volume":"171","author":"Zhu","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.034_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjd.14464","article-title":"Psychometric properties of the itch numeric rating scale in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Kimball","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.034_bib12","series-title":"American Academy of Dermatology 73rd Annual Meeting late-breaking research abstract book","article-title":"Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1)","author":"Gordon","year":"2015"},{"key":"10.1016\/j.jaad.2016.07.034_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2016.07.034_bib14","first-page":"AB191","article-title":"The Psoriasis Skin Appearance Bothersomeness (PSAB) measure for patients with moderate to severe plaque psoriasis [abstract]","volume":"70","author":"Naegeli","year":"2014","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216305631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216305631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:54Z","timestamp":1759272174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216305631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0190962216305631"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.034","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}